This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D70 | Synonyms: congenital neutropenia, Primary neutropenia, chronic congenital neutropenia
The history of congenital neutropenia began in 1956 when Kostmann described severe congenital neutropenia (agranulocytosis). However, congenital neutropenia covers a much broader category than Kostmann syndrome and is a heterogeneous group of diseases with various severities and mechanisms.
From the 1950s, neutropenia recurring in a cycle of about 21 days was observed in certain patient families and described as 'cyclic neutropenia'. Later, in the 2000s, it was found that cyclic neutropenia is caused mainly by autosomal dominant mutations of the ELANE (neutrophil elastase) gene.
From the 1970s to the 1990s, various forms of syndromic congenital neutropenia were described, such as Shwachman-Diamond syndrome (exocrine pancreatic insufficiency + neutropenia), myelokathexis (WHIM syndrome), and Cohen syndrome. The molecular basis of each disease was elucidated sequentially from the 1990s–2000s onward.
The Severe Chronic Neutropenia International Registry (SCNIR), begun in 1994, accumulated patient data from around the world and provided important information on natural history, the efficacy of G-CSF treatment, and the risk of leukemic transformation.
In Korea, the molecular diagnostic system for congenital neutropenia has been strengthened since the 2000s along with the development of pediatric hematology-oncology. Korean patient cases due to major causative genes such as ELANE and HAX1 have been reported in journals, and a rare disease registry project is under way.
| Syndrome | Gene (location) | Mode of inheritance | Characteristic symptoms |
|---|---|---|---|
| Shwachman-Diamond syndrome (SDS) | SBDS(7q11.21) | AR | Exocrine pancreatic insufficiency, growth failure, skeletal dysplasia |
| Myelokathexis/WHIM syndrome | CXCR4 (2q22.1) gain of function | AD | Skin warts, hypogammaglobulinemia, lymphopenia |
| Cohen syndrome | VPS13B(8q22-23) | AR | Intellectual disability, obesity, characteristic facial features |
| Barth syndrome | TAZ(Xq28) | X-linked | Cardiomyopathy, muscle weakness, 3-methylglutaconic aciduria |
| Glycogen storage disease type Ib | SLC37A4(11q23.3) | AR | Fasting hypoglycemia, hepatomegaly, chronic bowel disease |
Congenital neutropenia shows various modes of inheritance depending on the disease type. Autosomal dominant (AD): ELANE mutations, CXCR4 gain-of-function mutations. Autosomal recessive (AR): HAX1, G6PC3, SBDS, VPS13B, SLC37A4. X-linked: WAS gain-of-function mutations (XLN), TAZ (Barth syndrome).
The ELANE gene (19p13.3) encodes elastase, a serine protease of the primary granules of neutrophils. More than 250 mutations have been reported, and they can cause both severe congenital neutropenia and cyclic neutropenia.
SBDS gene mutations cause deficiency of a protein involved in ribosome maturation. Most are compound heterozygous mutations, and the mutations generally arise by gene conversion with the pseudogene (SBDSP).
Gain-of-function mutations of the CXCR4 gene (truncation of the C-terminus of CXCR4) cause persistent activation of CXCL12-CXCR4 signaling. As a result, release of mature neutrophils from the bone marrow is inhibited (myelokathexis). It is inherited in an autosomal dominant manner.
| Disease | Estimated prevalence |
|---|---|
| Severe congenital neutropenia (SCN) | About 1–2/1,000,000 |
| Cyclic neutropenia | About 1–2/1,000,000 |
| Shwachman-Diamond syndrome | About 1/76,000–1/200,000 |
| WHIM syndrome | Very rare, fewer than about 100 people worldwide |
| Cohen syndrome | About 1/100,000 in Finland |
In Korea, a systematic epidemiological survey covering all congenital neutropenia has not yet been conducted, but data are gradually accumulating in the rare disease registry system. Cases of Shwachman-Diamond syndrome and ELANE mutation-related SCN have been reported in Korean journals.
Neutrophils are the first-line defense cells against bacteria and fungi. At ANC <500/uL, the risk of bacterial infection increases markedly, and at ANC <100/uL, the risk of life-threatening infection is very high.
Recurrent bacterial infection is the key symptom in all congenital neutropenia. From early life, fever, recurrent pneumonia, skin infections (cellulitis, pyoderma), oral lesions (gingivitis, recurrent stomatitis, early tooth loss), perianal abscesses, lymphadenitis, and sepsis appear.
Gingivitis and oral ulcers are observed in almost all congenital neutropenia. Failure to thrive and abdominal distension (steatorrhea) in Shwachman-Diamond syndrome. Characteristic facial appearance in Cohen syndrome. Cardiomegaly in Barth syndrome.
| Test item | Result |
|---|---|
| ANC (severe SCN) | <500/uL, <200/uL in severe cases |
| Cyclic neutropenia | ANC fluctuation in a 21-day cycle; nadir <200/uL |
| WHIM syndrome | Decreased ANC + hypersegmented neutrophils on peripheral blood smear |
| Shwachman-Diamond | Possible trilineage cytopenia, low serum amylase/lipase |
SCN: maturation arrest at the promyelocyte or myelocyte stage. WHIM syndrome: accumulation of mature neutrophils (myelokathexis), hypersegmented nuclei, reduced granules. Shwachman-Diamond syndrome: hypocellularity, possible trilineage hypoplasia.
In children with recurrent bacterial infections, unexplained fever, oral ulcers, or gingivitis, a CBC is performed first. If ANC <1,500/uL persisting for 3 weeks or more is confirmed, a detailed workup is carried out. When cyclic neutropenia is suspected, CBC 2–3 times a week for 6–8 weeks is performed to confirm a periodic pattern of ANC fluctuation.
Autoimmune neutropenia of childhood is excluded by antineutrophil antibody (ANA antibody) testing. Differentiation from autoimmune neutropenia, which usually resolves spontaneously in children aged 18 months to 3 years, is important.
When Shwachman-Diamond syndrome is suspected, serum pancreatic enzymes (amylase, lipase), fat-soluble vitamins, and steatorrhea testing. When WHIM syndrome is suspected, immunoglobulin quantification and checking for HPV infection.
Bone marrow aspiration and biopsy evaluate the stage of neutrophil maturation, cellularity, and the state of trilineage hematopoiesis.
An NGS panel for causative genes of congenital neutropenia (including ELANE, HAX1, G6PC3, GFI1, SRP54, SBDS, CXCR4, VPS13B, TAZ, SLC37A4, etc.) is performed. If the panel is negative, whole exome or whole genome sequencing is considered.
Pancreatic exocrine function tests (fecal elastase, serum trypsinogen), abdominal CT/MRI (fatty replacement of the pancreas), SBDS gene analysis, skeletal X-rays (metaphyseal dysplasia).
Confirmation of a CXCR4 gain-of-function mutation, lymphocyte flow cytometry, serum immunoglobulins, HPV serotype testing.
In patients on G-CSF treatment, regular bone marrow examinations and monitoring for mutations such as CSF3R, RAS, and RUNX1 detect transformation to MDS/AML early.
In most congenital neutropenia, G-CSF (filgrastim) is the first-line treatment. Goal: maintain ANC >1,000/uL. The dose is individualized according to disease type and response.
The CXCR4 antagonist plerixafor (AMD3100) is under clinical study as a targeted therapy that induces release of mature neutrophils from the bone marrow in WHIM syndrome. Low-dose G-CSF and immunoglobulin replacement therapy are used concurrently.
Pancreatic enzyme replacement therapy (treatment of steatorrhea, improvement of growth failure). Neutrophil support with G-CSF. Hematopoietic stem cell transplantation (HSCT) is considered when bone marrow failure progresses.
Empirical broad-spectrum antibiotics for acute bacterial infections. Prevention and treatment of fungal infections (in some high-risk patients). Vaccination (inactivated vaccines).
| Disease | Prognosis |
|---|---|
| SCN(ELANE/HAX1) | Infections controlled with G-CSF in most cases. Risk of MDS/AML transformation 10–15% (10 years). Cure possible with successful HSCT. |
| Cyclic neutropenia | Episodes controlled with G-CSF. Low risk of AML transformation (about 2%). Relatively favorable. |
| Shwachman-Diamond syndrome | Risk of MDS/AML transformation (about 30% at 20 years). Survival after HSCT about 70–80%. |
| WHIM syndrome | Infection is the main cause of morbidity. Prognosis expected to improve with the introduction of plerixafor. |
Long-term follow-up is essential for all patients with congenital neutropenia. Regular bone marrow examinations and clonal monitoring, minimizing the G-CSF dose, and early treatment of infections are the keys to improving prognosis.
Continuous G-CSF treatment maintains ANC at or above an adequate level. Vaccination (pneumococcal, influenza, meningococcal, varicella). Prophylactic antibiotics (TMP-SMX) if needed. Oral hygiene care to prevent dental infections.
Genetic counseling for parents of patients with AR hereditary diseases (HAX1, SBDS, G6PC3, etc.). Prenatal genetic testing (CVS, amniocentesis) or PGT-M can be used.
In SCN patients on G-CSF treatment, bone marrow examination 1–2 times a year and monitoring for CSF3R, RUNX1, and RAS mutations. If abnormal clones or MDS findings are detected, G-CSF dose reduction and early consideration of HSCT.
G-CSF is adjusted to the minimum effective dose to minimize the clonal selection pressure associated with high-dose G-CSF use.